GlassScriptPhysician profile
Kelsey Carnahan
NPI 1083140578
$789.85
in general payments reported to CMS, 2019-2025
18 companies · $206 in 2025
The $206 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $74.92 · 2023: $192 · 2024: $317 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $101.26 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $99.98 | 2022-2024 | Bexsero, Shingrix, Arexvy |
| Cumberland Pharmaceuticals, INC. | $75.24 | 2024-2025 | Kristalose |
| Pfizer INC. | $61.32 | 2024-2025 | |
| Cranial Technologies, INC | $55.19 | 2022-2024 | Doc Band |
| Novo Nordisk INC | $52.20 | 2025 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $48.93 | 2023-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Dexcom, INC. | $44.72 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $42.94 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $33.65 | 2022-2024 | Zepbound, Mounjaro |
| Ucb, INC. | $28.58 | 2024 | Nayzilam |
| Seqirus USA INC | $24.58 | 2025 | Fluad, Flucelvax |
| Boston Scientific Corporation | $23.78 | 2024 | Advantage System |
| Organon LLC | $23.59 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $19.65 | 2023 | Prehevbrio |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $19.35 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Phadia US INC. | $18.55 | 2025 | Immunocap |
| Millicent US INC | $16.34 | 2024 | Femring, Intrarosa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Carnahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.